BIOA · NASDAQ · Biotechnology

BioAge Labs (BIOA)

Develops metabolic-disease drug candidates from human-aging biology.

$9.53
Pre-market−0.20 (−2.01%)
At close$9.73(+2.15%)

Something off on this page? Send us feedback.

Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$0.61
Revenue estimate
$1.5M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.36−$0.60−$0.56−$0.72−$0.52−$0.58−$0.58Pending
Estimate−$0.52−$0.56−$0.67−$0.83−$0.64−$0.65−$0.61−$0.61
Surprise+30.8%−7.1%+16.4%+13.3%+18.7%+10.8%+4.5%

RevenueReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported$1.5M$2.4M$2.1M$3.1M$2.8M$2.5M$2.5MPending
Estimate$580.0K$870.0K$1.1M$1.4M$1.1M$1.5M$1.5M$1.5M
Surprise+150.2%+177.2%+80.2%+119.9%+155.9%+63.7%+63.7%

History

DateEstimateReportedSurprise
Nov 2026−$0.61
Aug 2026−$0.61−$0.58+4.5%
Aug 2026−$0.65−$0.58+10.8%
May 2026−$0.64−$0.52+18.7%
Mar 2026−$0.83−$0.72+13.3%

The latest year is open to everyone — the 12 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Mar 2025
Nov 2024
Sep 2024
Mar 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Mar 2018−$0.72
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 5, 2026−$0.61$1.5M
Aug 6, 2026−$0.61−$0.58+4.5%$1.5M$2.5M+63.7%+4.0%
Aug 5, 2026−$0.65−$0.58+10.8%$1.5M$2.5M+63.7%+2.6%
May 8, 2026−$0.64−$0.52+18.7%$1.1M$2.8M+155.9%+0.9%
Mar 24, 2026−$0.83−$0.72+13.3%$1.4M$3.1M+119.9%+1.9%

The latest year is open to everyone — the 12 quarters behind it read with an account.

Sign in
Nov 6, 2025
Aug 6, 2025
May 6, 2025
Mar 20, 2025
Nov 7, 2024
Sep 26, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Mar 27, 2018−$0.72